MetLife Investment Management LLC Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

MetLife Investment Management LLC decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,967 shares of the biopharmaceutical company’s stock after selling 708 shares during the quarter. MetLife Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $29,400,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Brown Lisle Cummings Inc. lifted its position in Regeneron Pharmaceuticals by 18.2% in the second quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 10 shares during the last quarter. Sachetta LLC lifted its position in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the last quarter. Adirondack Trust Co. raised its position in shares of Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after acquiring an additional 10 shares in the last quarter. UMB Bank n.a. raised its stake in Regeneron Pharmaceuticals by 1.1% during the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after acquiring an additional 10 shares in the last quarter. Finally, Western Financial Corp CA grew its stake in Regeneron Pharmaceuticals by 0.7% during the 2nd quarter. Western Financial Corp CA now owns 1,819 shares of the biopharmaceutical company’s stock worth $1,912,000 after buying an additional 12 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.5 %

REGN opened at $753.03 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $735.95 and a 1 year high of $1,211.20. The firm has a 50 day moving average price of $929.13 and a 200 day moving average price of $1,024.43. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The company has a market cap of $82.75 billion, a PE ratio of 18.63, a price-to-earnings-growth ratio of 2.89 and a beta of 0.15.

Analyst Ratings Changes

REGN has been the topic of a number of recent research reports. Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Piper Sandler decreased their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Leerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Guggenheim upped their target price on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Finally, BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $1,099.55.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.